EMA Authorised: Metalyse (tenecteplase) — Boehringer Ingelheim International GmbH

View source ↗

Summary

The European Medicines Agency authorised Metalyse (tenecteplase) by Boehringer Ingelheim International GmbH for the treatment of myocardial infarction. The deci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• Metalyse (tenecteplase)

Snippet

Status: Authorised. Therapeutic area: Myocardial Infarction. MAH: Boehringer Ingelheim International GmbH. Decision date: 19/06/2025